IL277095B2 - Preparations containing anti-PD-1 antibody - Google Patents
Preparations containing anti-PD-1 antibodyInfo
- Publication number
- IL277095B2 IL277095B2 IL277095A IL27709520A IL277095B2 IL 277095 B2 IL277095 B2 IL 277095B2 IL 277095 A IL277095 A IL 277095A IL 27709520 A IL27709520 A IL 27709520A IL 277095 B2 IL277095 B2 IL 277095B2
- Authority
- IL
- Israel
- Prior art keywords
- pharmaceutical composition
- seq
- amino acid
- acid sequence
- sequence shown
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862639587P | 2018-03-07 | 2018-03-07 | |
| US201962807912P | 2019-02-20 | 2019-02-20 | |
| PCT/IB2019/051733 WO2019171253A1 (en) | 2018-03-07 | 2019-03-04 | Anti-pd-1 antibody compositions |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| IL277095A IL277095A (en) | 2020-10-29 |
| IL277095B1 IL277095B1 (en) | 2025-06-01 |
| IL277095B2 true IL277095B2 (en) | 2025-10-01 |
Family
ID=66041593
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL277095A IL277095B2 (en) | 2018-03-07 | 2019-03-03 | Preparations containing anti-PD-1 antibody |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20210002369A1 (OSRAM) |
| EP (1) | EP3761954A1 (OSRAM) |
| JP (1) | JP7312188B2 (OSRAM) |
| KR (1) | KR102594028B1 (OSRAM) |
| CN (1) | CN112105343B (OSRAM) |
| AU (1) | AU2019232625B2 (OSRAM) |
| BR (1) | BR112020017935A2 (OSRAM) |
| IL (1) | IL277095B2 (OSRAM) |
| MX (1) | MX2020009275A (OSRAM) |
| WO (1) | WO2019171253A1 (OSRAM) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20200087390A1 (en) | 2016-12-21 | 2020-03-19 | Amgen Inc. | Anti-tnf alpha antibody formulations |
| SG11202108627SA (en) | 2019-02-18 | 2021-09-29 | Lilly Co Eli | Therapeutic antibody formulation |
| CA3160806A1 (en) * | 2019-11-13 | 2021-05-20 | Pfizer Inc. | Stable aqueous formulation containing anti-tfpi antibody _______ |
| EP4074338A4 (en) * | 2019-12-13 | 2024-03-06 | Samsung Bioepis Co., Ltd. | PHARMACEUTICAL PREPARATION OF STABLE ANTI-PD-1 ANTIBODY |
| US20230355757A1 (en) | 2019-12-20 | 2023-11-09 | Formycon Ag | Formulations of anti-pd1 antibodies |
| CN115397394A (zh) * | 2020-01-31 | 2022-11-25 | 赛诺菲 | 抗体的肺部递送 |
| MA59827B1 (fr) | 2020-05-26 | 2024-10-31 | Boehringer Ingelheim International Gmbh | Anticorps anti-pd-1 |
| CN113967195A (zh) * | 2020-07-22 | 2022-01-25 | 三生国健药业（上海）股份有限公司 | 抗her2/pd1双特异性抗体冻干制剂及其制备方法 |
| EP4359001A1 (en) | 2021-06-23 | 2024-05-01 | Formycon AG | Formulations of anti-pd1 antibodies |
| WO2023274275A1 (zh) * | 2021-07-01 | 2023-01-05 | 天津立博美华基因科技有限责任公司 | 药物组合及其用途 |
| PE20240797A1 (es) * | 2021-07-09 | 2024-04-18 | Macrogenics Inc | Composiciones farmaceuticas de un anticuerpo contra pd-1 y uso de las mismas |
| EP4395816A4 (en) * | 2021-09-03 | 2025-07-30 | Dr Reddys Laboratories Ltd | PHARMACEUTICAL FORMULATION OF IMMUNE CHECKPOINT INHIBITORS |
| EP4395815A4 (en) * | 2021-09-03 | 2025-07-30 | Dr Reddys Laboratories Ltd | METHOD FOR IMPROVING THE STABILITY OF IMMUNE CHECKPOINT INHIBITORS |
| AU2023229902A1 (en) * | 2022-03-07 | 2024-08-29 | Mabxience Research, S.L. | Stable formulations for antibodies |
| EP4637818A1 (en) | 2022-12-21 | 2025-10-29 | Formycon AG | Formulations of anti-pd1 antibodies |
| IL322410A (en) | 2023-02-16 | 2025-09-01 | Sun Pharmaceutical Ind Ltd | Stable protein complexes containing an antibody against PD1 |
| KR20260054696A (ko) * | 2023-08-16 | 2026-04-22 | 상하이 맙젠 바이오텍 리미티드 | 면역접합체를 포함하는 약학적 조성물 및 이의 용도 |
| SE548163C2 (en) * | 2024-02-16 | 2026-04-13 | Xbrane Biopharma Ab | Stable antibody formulation comprising nivolumab, histidine, sucrose, polysorbate and methionine |
| WO2025174319A1 (en) * | 2024-02-16 | 2025-08-21 | Xbrane Biopharma Ab | Stable antibody formulation for intravenous use comprising nivolumab, histidine, sucrose, polysorbate and methionine |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015048520A1 (en) * | 2013-09-27 | 2015-04-02 | Genentech, Inc. | Anti-pdl1 antibody formulations |
| US20160159905A1 (en) * | 2014-12-09 | 2016-06-09 | Rinat Neuroscience Corp. | Anti-pd-1 antibodies and methods of use thereof |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| LT2620450T (lt) * | 2005-03-08 | 2019-02-11 | Pfizer Products Inc. | Anti-ctla-4 antikūnų kompozicijos |
| CN101146553A (zh) * | 2005-03-23 | 2008-03-19 | 辉瑞产品公司 | 用于治疗癌症的抗-ctla4抗体和吲哚酮组合治疗 |
| PL2161336T5 (pl) | 2005-05-09 | 2017-10-31 | Ono Pharmaceutical Co | Ludzkie przeciwciała monoklonalne przeciwko białku Programmed Death 1 (PD-1) oraz sposoby leczenia raka z zastosowaniem samych przeciwciał anty-PD-1 lub w połączeniu z innymi środkami immunoterapeutycznymi |
| KR101586617B1 (ko) | 2007-06-18 | 2016-01-20 | 머크 샤프 앤 도메 비.브이. | 사람 프로그램된 사멸 수용체 ｐｄ-1에 대한 항체 |
| ES2545609T3 (es) | 2008-08-25 | 2015-09-14 | Amplimmune, Inc. | Composiciones de antagonistas de PD-1 y métodos de uso |
| EA201291181A1 (ru) * | 2010-05-06 | 2013-05-30 | Новартис Аг | Композиции и способы применения терапевтических поливалентных антител против белка, родственного рецептору липопротеинов низкой плотности 6 (lrp6) |
| SG193964A1 (en) | 2011-04-07 | 2013-11-29 | Glaxosmithkline Llc | Formulations with reduced viscosity |
| TW202214691A (zh) * | 2014-03-21 | 2022-04-16 | 美商艾伯維有限公司 | 抗-egfr抗體及抗體藥物結合物 |
| TW201617368A (zh) * | 2014-09-05 | 2016-05-16 | 史坦森特瑞斯公司 | 新穎抗ｍｆｉ２抗體及使用方法 |
| AU2016210918A1 (en) * | 2015-01-28 | 2017-07-13 | Pfizer Inc., | Stable aqueous anti- vascular endothelial growth factor (VEGF) antibody formulation |
| MX395336B (es) * | 2015-09-28 | 2025-03-25 | Suzhou Suncadia Biopharmaceuticals Co Ltd | Preparacion farmaceutica de anticuerpo anti-pd-1 estable y aplicacion del mismo en medicina. |
| WO2017055966A1 (en) * | 2015-10-01 | 2017-04-06 | Pfizer Inc. | Low viscosity antibody compositions |
| CA3061050A1 (en) * | 2017-05-02 | 2018-11-08 | Merck Sharp & Dohme Corp. | Stable formulations of anti-tigit antibodies alone and in combination with programmed death receptor 1 (pd-1) antibodies and methods of use thereof |
| WO2018211517A1 (en) * | 2017-05-16 | 2018-11-22 | Bhami's Research Laboratory, Pvt. Ltd. | High concentration protein formulations with reduced viscosity |
-
2019
- 2019-03-03 IL IL277095A patent/IL277095B2/en unknown
- 2019-03-04 KR KR1020207028149A patent/KR102594028B1/ko active Active
- 2019-03-04 JP JP2020546926A patent/JP7312188B2/ja active Active
- 2019-03-04 US US16/978,354 patent/US20210002369A1/en active Pending
- 2019-03-04 BR BR112020017935-3A patent/BR112020017935A2/pt unknown
- 2019-03-04 CN CN201980030480.7A patent/CN112105343B/zh active Active
- 2019-03-04 MX MX2020009275A patent/MX2020009275A/es unknown
- 2019-03-04 EP EP19715555.9A patent/EP3761954A1/en active Pending
- 2019-03-04 WO PCT/IB2019/051733 patent/WO2019171253A1/en not_active Ceased
- 2019-03-04 AU AU2019232625A patent/AU2019232625B2/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015048520A1 (en) * | 2013-09-27 | 2015-04-02 | Genentech, Inc. | Anti-pdl1 antibody formulations |
| US20160159905A1 (en) * | 2014-12-09 | 2016-06-09 | Rinat Neuroscience Corp. | Anti-pd-1 antibodies and methods of use thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| US20210002369A1 (en) | 2021-01-07 |
| JP2021517129A (ja) | 2021-07-15 |
| RU2020129226A (ru) | 2022-04-07 |
| WO2019171253A1 (en) | 2019-09-12 |
| CA3093036A1 (en) | 2019-09-12 |
| RU2020129226A3 (OSRAM) | 2022-04-07 |
| CN112105343A (zh) | 2020-12-18 |
| AU2019232625B2 (en) | 2025-12-11 |
| KR102594028B1 (ko) | 2023-10-24 |
| AU2019232625A1 (en) | 2020-09-17 |
| KR20200128115A (ko) | 2020-11-11 |
| BR112020017935A2 (pt) | 2021-02-09 |
| WO2019171253A8 (en) | 2020-10-01 |
| IL277095A (en) | 2020-10-29 |
| EP3761954A1 (en) | 2021-01-13 |
| JP7312188B2 (ja) | 2023-07-20 |
| CN112105343B (zh) | 2024-07-30 |
| IL277095B1 (en) | 2025-06-01 |
| MX2020009275A (es) | 2021-01-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL277095B1 (en) | Anti-pd-1 antibody compositions | |
| JP2021517129A5 (OSRAM) | ||
| JP5933975B2 (ja) | 抗体製剤 | |
| ES2626033T3 (es) | Formulaciones de anticuerpo a alta concentración | |
| ES2439641T3 (es) | Composiciones y procedimientos de producción de una composición | |
| JP2007532660A (ja) | 抗−ｉｌ−９抗体製剤及びその使用法 | |
| US20220135689A1 (en) | Anti-hla-g antibodies, compositions comprising anti-hla-g antibodies and methods of using anti-hla-g antibodies | |
| HRP20211444T1 (hr) | Anti-dll3 antitijelo | |
| PE20240814A1 (es) | Formulaciones estables de anticuerpos contra el receptor de muerte programada 1 (pd-1) y metodos para su uso | |
| RU2012131099A (ru) | Препарат антитела | |
| JP2020518600A5 (OSRAM) | ||
| CO6251275A2 (es) | Formulaciones de inmunoglobulina liofilizadas y metodos para su preparacion | |
| MY182680A (en) | Antibody formulation and therapeutic regimens | |
| JP2020518598A5 (OSRAM) | ||
| PE20140882A1 (es) | Anticuerpos neutralizantes de citomegalovirus humano | |
| MX363226B (es) | Formulaciones de anticuerpos. | |
| TW201726168A (zh) | 抗ｃｄ３８抗體之皮下調配物及其用途 | |
| CN107257692A (zh) | Il‑17抗体的药物产品和稳定液体组合物 | |
| RU2017111228A (ru) | Композиции антитела против IL-7R | |
| PE20120899A1 (es) | Composiciones y metodos para anticuerpos que se dirigen a la proteina de complemento c3b | |
| JP2020518600A (ja) | 単独のおよびプログラム死受容体１（ｐｄ−１）抗体と組み合わされた抗ｔｉｇｉｔ抗体の安定な製剤、ならびにその使用方法 | |
| PE20251257A1 (es) | Formulaciones de inmunoconjugado anti-cd79b estables | |
| WO2019165077A1 (en) | B7-h4 antibody formulations | |
| AR115365A1 (es) | Formulaciones de anticuerpos anti-pd-l1 humanos | |
| IL273384B2 (en) | Methods of preventing methionine oxidation in immunoconjugates |